Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Dermatologic 1

Conditions

Leukemia 4Lymphoma, Non-Hodgkin 3Leukemia, Myeloid, Acute 3Congenital Abnormalities 3Colonic Neoplasms 3Somatostatinoma 2Recurrence 2Myeloproliferative Disorders 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Islet Cell 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Vipoma 1Uterine Cervical Dysplasia 1Urologic Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocythemia, Essential 1Squamous Intraepithelial Lesions 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pituitary Neoplasms 1

Interventions

Capecitabine 6Temozolomide 5Octreotide 4Leucovorin 4Everolimus 4Fluorouracil 3Bevacizumab 3vatalanib 2pentetreotide 2Trastuzumab 2Sunitinib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Cisplatin 2Bortezomib 2Biological Therapy 2veliparib 1tipifarnib 1temsirolimus 1sapanisertib 1romidepsin 1regorafenib 1pazopanib 1palbociclib 1motesanib diphosphate 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1gallium Ga 68 dotatate 1dehydroftorafur 1cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Somatostatinoma × Biological Therapy × Clear all
NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡